## Data extraction form used in systematic review

Reviewer:				
Date form completed:				
Title:				
Author(s):				
Year Published:				
Citation (incl. doi):				
Type of study:	Trial-based EE □	Model-ba	sed EE □	Non-EE modelling study □
Economic evaluation deta	ails (if applicable)	N/A		Location in text (page/figure/ table/other)
Objective/decision problem:				,
Patient population				
characteristics (describe):				
Location (country/city):				
Setting (describe):				
<b>Economic study design:</b>				
	CEA		CBA	
	CUA		CMA	
	COA	_	CIVIT	
	CCA		Cost(s) onl	у 🗆
	Health outcomes(s) only			
Perspective of analysis:				
	Societal		Individual clinician	
	Patient and patient		Cimician	
	family	□ Insure	Insurer/thi	rd 🗆
	U a altibación accestación		party paye	r
	Healthcare system	Ш	Othory	
	Healthcare provider		Other:	
Primary				
costs/consequences/outcome				
measure(s) (please list):				
Strategies/comparators:				
Time horizon of analysis:				
Was discounting used? (state annual or otherwise)	Discount rate for costs:			
	Discount rate for health	outcomes	:	
	No Discounting			
	N/A (no information/no	ot relevant)		

Modelling details (if applicable) N/A $\square$						ocation in text
[Adapted from Philip	s 2006 and	Veme	er 201	6 (AdViSHE) checklists]		page/figure table/other)
Model type		Coho	ort-bas	sed decision tree (DT)		
				sed State Transition model		
		(MM	1)			
		Indiv	idual <sub>l</sub>	patient-level DT		
		Indiv	ridual <sub>l</sub>	patient-level MM		
		Discr	ete ev	vent simulation		
		Ager	nt-base	ed model		
		Syste	em dyı	namics model		
		Othe	er:			
Rationale for model type	<b>:</b> :	Yes		If Yes please specify:		
<b>16</b> 11 4 4 4		No				
Model structure (paste s						
Rationale for model stru	cture:	Yes		If Yes please specify:		
		No				
Structural assumptions,	incl. cycle					
length (describe):						
Have experts been asked	l to judge	Yes		If Yes please specify:		
the appropriateness of tl	ne model?	No		<ol> <li>Who:</li> <li>Why they are experts:</li> </ol>		
				3. Level of agreement:		
Has the model been com	pared with	Yes		If Yes please provide		
other models found in th	-	No		reference/citation:		
literature?			_			
Was patient heterogenei	ty	Yes		If Yes please		
modelled?	•	No		specify:		
Source of data for	1 Meta-ana	lysis o	f RCTs	s with direct comparison betwee	n	
clinical effect sizes,	comparator	therap	ies, me	easuring final outcomes.	_	
adverse events &	2 Single RCT with direct comparison between comparator			or 🗌		
complications:	therapies, measuring final outcomes					
	3 Meta-analysis of RCTs with direct comparison between comparator therapies, measuring surrogate outcomes			n 🗆		
	Meta-analysis of placebo-controlled RCTs with similar trial populations, measuring final outcomes for each individual □					
	therapy					

Modelling details (if	applicable) N/A □	Location in text
[Adapted from Philips	s 2006 and Vemer 2016 (AdViSHE) checklists]	(page/figure /table/other)
	<b>4</b> Single RCT with direct comparison between comparator therapies, measuring surrogate outcomes	
	Single placebo-controlled RCTs with similar trial populations, measuring final outcomes for each individual therapy	
	5 Meta-analysis of placebo-controlled RCTs with similar trial populations, measuring surrogate outcomes	
	<b>6</b> Single placebo-controlled RCTs with similar trial populations, measuring surrogate outcomes for each individual therapy	
	7 Case-control or cohort studies	
	8 Non-analytic studies, for example, case reports, case series □	
	9 Expert opinion	
	0 Not stated	
	Other:	
	Specify relevant data sources:	
	More than 1 data source per parameter?	
	Reasons for excluding data sources?	
	Evidence synthesis performed?	
	Calibration?	
Source of baseline clinical data:	1 Case series or analysis of reliable administrative databases specifically conducted for the study covering patients solely from the jurisdiction of interest.	
	<b>2</b> Recent case series or analysis of reliable administrative databases covering patients solely from the jurisdiction of interest.	
	3 Recent case series or analysis of reliable administrative databases covering patients solely from another jurisdiction. $\Box$	
	4 Old case series or analysis of reliable administrative databases. Estimates from RCTs □	
	<b>5</b> Estimates from previously published economic analyses: unsourced	
	6 Expert opinion	
	0 Not stated	
	Other:	

Modelling details (if applicable) N/A $\square$						
[Adapted from Philip	s 2006 and Vemer 2016 (AdViSHE) checklists]	<b>text</b> (page/figure /table/other)				
	Specify relevant data sources:  More than 1 data source per parameter? Reasons for excluding data sources? Evidence synthesis performed? Calibration?					
Source of data for	1 Analysis of reliable administrative databases					
duration of primary	specifically conducted for the study covering patients					
effect (i.e. after end of	solely from the jurisdiction of interest					
follow-up of source of primary effect size)	<b>2</b> Recent analysis of reliable administrative databases covering patients solely from the jurisdiction of interest					
	<b>3</b> Recent analysis of reliable administrative databases covering patients solely from another jurisdiction					
	4 Old analysis of reliable administrative databases.					
	<b>5</b> Estimates from previously published economic analyses: unsourced					
	<b>6</b> Expert opinion					
	<b>0</b> Not stated					
	Other:					
	Specify relevant data sources:  More than 1 data source per parameter?  Reasons for excluding data sources?  Evidence synthesis performed?  Calibration?					
Source of data for	1 Prospective data collection or analysis of reliable					
resource use:	administrative data from same jurisdiction for specific study					
	<b>2</b> Recently published results of prospective data collection or recent analysis of reliable administrative data – same jurisdiction					
	<b>3</b> Unsourced data from previous economic evaluations – same jurisdiction					
	<b>4</b> Recently published results of prospective data collection or recent analysis of reliable administrative data – different jurisdiction					
	<b>5</b> Unsourced data from previous economic evaluation – different jurisdiction					

Modelling details (if applicable	e) N/A 🗆	Location in text
[Adapted from Philips 2006 and	Vemer 2016 (AdViSHE) checklists]	(page/figure /table/other)
<b>6</b> Expert op	oinion	
<b>0</b> Not stat		
Other:		
Specif	y relevant data sources:	Ш
More t	han 1 data source per parameter?	
Reason	s for excluding data sources?	
Eviden	ce synthesis performed?	
Calibra	ition?	
Are methods for identifying and	Yes	
synthesising input data reported?	No □ If Yes please specify:	
Were all data sources described	Yes	
and reported?	No 🗆	
Were mutually inconsistent data	Yes ☐ If Yes were the choices	
reported in the model?	No ☐ justified?	
Model uncertainty	Methodological uncertainty ☐  If yes, describe:  Structural uncertainty ☐  If yes, describe:  Heterogeneity ☐	
	If yes, list subgroups:  Parameter uncertainty  If yes, list method:	
Have experts been asked to judge	Yes If Yes please specify:	
the appropriateness of the input data?	□No 1. Who: 2. Why they are experts: 3. Level of agreement:	
When input parameters are based on regression models, have statistical tests been performed?	Yes If Yes please specify tests:  □No	
_		
Model internal validation (mathematical logic and accuracy	Computerised model examined by modelling experts	
of coding)	Model run for specific, extreme sets of	
	parameter values to detect coding errors	_
	Patients tracked through model to determine if its	
	logic is correct	
	Tested individual sub-modules of the computerised model Internal validation not reported:	
Model external validation	Model outcomes assessed by experts	

Modelling details (if applicable) N/A $\square$						
[Adapted from Philips 2006 and Vemer 2016 (AdViSHE) checklists]						
	Model outcomes compared with the outcomes of other models that address similar problems					
	1					
	Model outcomes compared with the outcomes					
	obtained when using alternative input data					
	Model outcomes compared with empirical data					
	Model calibrated against independent data with					
	differences explained and justified					
	Counterintuitive results from model explained					
	and justified					
	External validation not reported:					
Other model validation (describe):						

Data dataila (all anal	(zvana)					Location in
Data details (all anal [Adapted from Coyle		d with	h additional ite	ems]		text (page/figure /table/other)
Costs included:	Direct medical		Direct non- medical		Productivity losses	,
	Direct treatment		Social care		Income	
	In-patient		Social benefits		forgone due to illness	
	Out-patient		Travel costs		Income	
	Day care		Caregiver		forgone due to death	
	Community healthcare		out-of- pocket		Income forgone due	
	Medication		Criminal		to death	
	Side effect costs		Justice Training of			
	or		staff			
	Staff					
	Medication					
	Labs/diagnosti					
	С					
	Overhead Capital					
	equipment					
	Real estate					
	Other:					
Source of data for costs:	1 Cost calculations based on reliable databases or data sources conducted for specific study – same jurisdiction					
	2 Recently published cost calculations based on reliable databases or data sources – same jurisdiction					

	3 Unsourced data from previous economic evaluation – same jurisdiction	е
	4 Recently published cost calculations based on reliable databases or data sources – different jurisdiction	
	<b>5</b> Unsourced data from previous economic evaluation – different jurisdiction	
	6 Expert opinion	
	0 Not stated	
	Other:	
	Specify relevant data sources:	_
	More than 1 data source per parameter?	
	Reasons for excluding data sources?	
	Evidence synthesis performed?	
	Calibration?	
Source of data for utilities:	1 Direct utility assessment for the specific study from a sample either:  (a) of the general population, or (b) with knowledge of the disease(s) of interest, or (c) of patients with the disease(s) of interest	
	Indirect utility assessment for the specific study from patient sample with disease(s) of interest, using a tool validated for the patient population	_
	2 Direct utility assessment from a previous study from a sample either:  (a) of the general population, or (b) with knowledge of the disease(s) of interest, or (c) of patients with the disease(s) of interest	
	Indirect utility assessment from a previous study from patient sample with disease(s) of interest, using a tool validated for the patient population	<b>-</b>
	3 Indirect utility assessment from a patient sample with disease(s) of interest, using a tool <u>not</u> validated for the patient population	<b>-</b>
	Patient preference values obtained from a visual analogue scale	
	4 Delphi panels, expert opinion	
	<b>0</b> Not clearly stated	
	Other: Expecify relevant data sources:	
	·	
	Reasons for excluding data sources?	
	Evidence synthesis performed?	
	7	

	Calibration?		
Were QOL estimates	Yes □		
derived:	No 🗆		
If validated tools wer used, which	e Rosser Index	☐ Health Utilities Index (HUI)	
instrument(s):	EQ-5D	☐ Quality of Well Being (QWB)	
	15D		
	SF-12	SF-36 □	
Converted into	Yes	SF-6	
utilities?	No □ If Yes report value set:		
If direct elicitation	Standard Gamble		_
was used, which	VAS/rating scale		
approach(s):	Time trade-off ☐ Person trade-off	]	
Utility values	Yes		
combined with	No $\square$		
survival to form			
QALYs?			
Study results			Location in text (page/figure/ table/other)
Currency and cost year			table/offici)
Cost-effectiveness	Point estimate:		
results (e.g. ICER)	Probabilistic results (proba	ability of being cost-effective):	
Study conclusions	Trocucinous resums (proce	weining of desing cost enfouries.	
Quality and risk of	of bias for economic ev	valuations (if applicable)	N/A □
Checklists completed	: CHEC (all EE) □	ISPOR (models only) $\square$	
Risk of bias [CHEC, ISPOR]:	High □ M	Iedium □ Low □ Unknown	n 🗆
Comments on study			
quality and limitation	ns:		